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Abstract
Background: The pregnancy hormone human chorionic gonadotropin (hCG) and its free subunits (hCG alpha, hCG
beta) are produced in the male reproductive tract and found in high concentrations in seminal fluid, in particular
hCG alpha. This study aimed to elucidate changes in peptide hormone profiles in patients showing abnormal
semen analyses and to determine the genuineness of the highly abundant hCG alpha.
Methods: Seminal plasma was obtained from 45 male patients undergoing semen analysis during infertility
workups. Comprehensive peptide hormone profiles were established by a panel of immunofluorometric assays for
hCG, hCG alpha, hCG beta and its metabolite hCG beta core fragment, placental lactogen, growth hormone and
prolactin in seminal plasma of patients with abnormal semen analysis results (n = 29) versus normozoospermic
men (n = 16). The molecular identity of large hyperglycosylated hCG alpha was analyzed by mass-spectrometry
and selective deglycosylation.
Results: hCG alpha levels were found to be significantly lower in men with impaired semen quality (1346 +/- 191
vs. 2753 +/- 533 ng/ml, P = 0.022). Moreover, patients with reduced sperm count had reduced intact hCG levels
compared with normozoospermic men (0.097 +/- 0.022 vs. 0.203 +/- 0.040 ng/ml, P = 0.028). Using mass-
spectrometry, the biochemical identity of hCG alpha purified from seminal plasma was verified. Under non-
reducing conditions in SDS-PAGE, hCG alpha isolated from seminal plasma migrated in a manner comparable with
large free hCG alpha with an apparent molecular mass (Mr, app) of 24 kDa, while hCG alpha dissociated from
pregnancy-derived holo-hCG migrated at approximately 22 kDa. After deglycosylation with PNGase F under
denaturing conditions, all hCG alpha variants showed an Mr, app of 15 kDa, indicating identical amino acid
backbones.
Conclusions: The findings indicate a pathophysiological relevance of hCG, particularly its free alpha subunit, in
spermatogenesis. The alternative glycosylation pattern on the free large hCG alpha in seminal plasma might reflect
a modified function of this subunit in the male reproductive tract.
Background
Male fertility abnormalities are diagnosed by physical
examination, endocrine parameters and assessment of
semen quality. Endocrine analyses include hormones of
the pituitary testicular axis, i.e. pituitary-derived gonado-
tropins luteinizing hormone (LH), follicle stimulating
hormone (FSH), total testosterone (TT) and free/bioa-
vailable testosterone. Other hormones, such as prolactin
(hPRL), estrogen, or stress hormones, are also important
parameters of the male fertility workup.
Apart from serum hormone levels, investigators
sought molecular markers of spermatogenesis in seminal
plasma. Such markers were anti-Mullerian hormone,
inhibin B [1], and transferrin. Although a few attempts
have been made to correlate human chorionic gonado-
tropin (hCG) and hCG-like molecules to spermatogen-
esis [2-9], the molecular heterogeneity of molecular
hCG species in various body fluids, the lack of appropri-
ate standards of hCG-variants, undefined molecular
recognition profiles of immunoassay analyses and inter-
pretation of marker profiles has, until recently, been too
poor to do so [10] (the molecular structures of hCG and
its variants are schematically depicted in Figure 1). The
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of its Tissue Differentiation (TD) program, the interna-
tional TD-7 Workshop on antibodies to hCG and hCG-
related molecules and recommended epitope combina-
tions for 2-site immunoassays for the measurement and
determination of members of the molecular hCG family
[11]. With our selective panel of immunofluorometric
assays (IFMAs) based on the reference monoclonal anti-
bodies (mAbs) of the TD-7 Workshop [12], we pre-
viously investigated the abundance of hCG and hCG-
like molecules in seminal plasma of healthy fertile men
and found significant differences between the hCG mar-
ker profile and that of other hCG-containing physiologi-
cal body fluids [13]. During pregnancy, the a/b-
heterodimer hCG is present in vast molar excess in
serum, as is hCGb/hCGbcf (hCGb core fragment) in
urine, but in seminal plasma, the subunit hCGa was by
far the most prominent marker of the hCG molecular
family, with concentrations as high as that found during
p r e g n a n c yi ne x t r a e m b r y o n i cc o e l o m i cf l u i d ,a n d
approximately 10,000-fold higher than in normal male
serum. hCGb and holo-hCG concentrations were found
to be 1000-fold and 10,000-fold less than hCGa,
whereas hCGbcf levels were mostly undetectable in
seminal plasma [13].
In the present study, the local profile of endocrine
parameters, i.e. hCG-like substances and the family of
protein hormones prolactin (hPRL), growth hormone
(GH) and placental lactogen (PL), was analyzed in semi-
nal plasma of men with abnormal semen analysis find-
ings and compared to normozoospermic men to clarify
ap o s s i b l ep a t h o p h y s i o l o g i c a lr o l eo ft h e s eh o r m o n e si n
spermatogenesis disorders. An important question was
whether the highly abundant hCGa is genuine hCGa or
a moderately-defined hCGa-like substance. Thus, the
glycosylation pattern of hCGa, which has two N-glyco-
sylation sites at Asn
52 and Asn
78 [14], was purified from
seminal plasma and the isolated protein analyzed by
mass-spectrometry.
Methods
Determination of serum hormone levels
All blood samples were obtained between 8 and 10 a.m.
and were immediately transferred to the laboratory for
further processing. Hormonal analyses included the
determination of FSH, LH, TT and hPRL. FSH and LH
analysis was performed using a standard two step
immunoassay (Architect FSH, Abbott; ref. B7K750;
Architect LH, Abbott; ref. 34-4522/R8). hPRL levels
were determined by the two-step immunoassay Archi-
tect Prolactin (Abbott; ref. B7K760), TT levels by the
Architect Testosterone Assay (Abbott; ref. B7K730). All
assays were performed according to manufacturer’s
instructions.
Semen samples
Human semen samples were collected after 4 days of
ejaculatory continence from 45 male patients under-
going semen analysis as part of an infertility workup at
the Andrology Division of the Department of Derma-
tology, Univ. of Erlangen-Nuremberg, Germany,
between 1995 and 1997. Semen samples were obtained
and processed as recommended in the WHO Labora-
tory Manual for the Examination of Human Semen
and Semen-Cervical Mucus Interaction [15]. None
revealed the presence of antisperm antibodies in their
seminal plasma or sera as shown by the immunobead
technique [16]. The seminal fluid remaining after rou-
tine testing was aspirated from the spermatozoal pellet
a n ds t o r e da t- 2 0 ° Cu n t i lu s e .A f t e rt h a w i n g ,t h es e m i -
nal fluids were centrifuged at 40,000 × g to remove
residual debris and then assayed. All patients gave
written informed consent.
Semen analysis
Semen analysis was performed by determination of pH,
liquefaction time, volume, total and progressive motility at
60 min after ejaculation, sperm/round cell/germ cell/leu-
kocyte counts, and the total and specific head/midpiece/
tail percentage of abnormal forms according to the WHO
criteria of 1995. Morphology was determined on metha-
nol-fixed (2.5 min) and giemsa-stained (10 min) sperm
smears by light microscopy and by two independent
observers by using the strict Kruger criteria. Viability of
sperm was measured by eosin Y staining. The
Figure 1 Schematic depiction of the molecular structures of
the cystine knot growth factor hCG and of hCG-variants. hCG
consists of an a-subunit (hCGa) with 92 amino acids (aa) in length
non-covalently linked to the hCGb-subunit (145 aa). Nicked hCG
(hCGn) and nicked hCGb (hCGbn) contain nicks in the region of aa
hCGb44-48 and rarely around aa 77 of hCGb. The most important
metabolic product of hCG is the hCGb core fragment (hCGbcf),
which is composed of two peptides encompassing aa hCGb6-40
and 55 to 92 covalently linked. The hCG-unique carboxyl-terminal
peptide (CTP) is clipped and truncated hCG and hCGb variants are
generated (-CTPhCG and -CTPhCGb). There are a multitude of
glycosylation variants involving both N-glycosylated (hCGa aa 52 &
78, hCGb aa 13 & 30) and O-glycosylated carbohydrate antennae
(hCGb aa Ser 121, 127, 132, 138) [41,42].
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blood cells was measured by peroxidase staining.
Patients were grouped according to their semen analysis;
abnormal semen results (n = 29): oligoasthenoteratozoos-
permia (OAT, n = 7), asthenoteratozoospermia (n = 2),
asthenozoospermia (n = 3), teratozoospermia (n = 1), oli-
gozoospermia (n = 2), cryptozoospermia (n = 8), azoosper-
mia (n = 6), and normozoospermic men (n = 16).
Time-resolved immunofluorometric assays
Generation and characterization of monoclonal Antibo-
dies (mAbs) against intact hCG, hCGb,h C G bcf, hCGa
and FSH and GH, hPRL and PL has been described in
detail [17-20]. The mAbs against hCG/hCG-variants
were previously used as reference reagents in the inter-
national TD-7 Workshop on antibodies to hCG and
hCG-related molecules [11]. Sensitive and specific
IFMAs for hCG, free hCGa, free hCGb and the hCGbcf,
respectively, were developed on the basis of our panel of
mAbs [21,22]. MAb pairs for each of the four IFMAs
were selected on the basis of antigen specificity, epitope
localization and compatibility [11,17,18,23-25].
IFMAs were performed as published previously
[26,27]. Samples were diluted in 0.01 mol/l NaHCO3
containing 0.1% bovine serum albumin (BSA).
The National Institute for Biological Standards and
Control (NIBSC; South Mimms, UK) kindly provided
the International Standards (IS) for hCG IS75/537,
hCGb IS 75/551, hCGa IS 74/569. Highly purified
hCGbcf was a gift by Drs. Klaus Mann and Rudy Hoer-
mann (Essen, Germany).
Coating mAbs were coded as INN(sbruck)-hCG-45
(hCG+hCGn-assay), -68 (hCGb-assay), -106 (hCGbcf-
assay) and INN-hCG-72 (hCGa-assay). The detection
mAbs (INN-hFSH-158 for the hCGa-assay were direc-
ted against epitope a3, presumably located on loop 3 of
GPHa.T oi m p r o v ea s s a yh o m o g e n e i t y ,as i n g l em A b
(code: INN-hCG-22) recognizing a broad spectrum of
hCG and hCG-like molecules, i.e. hCG, nicked hCG
(hCGn), hCG lacking the carboxyl-terminal peptide of
the b-subunit (-CTPhCG), hCGb,h C G bn, -CTPhCGb
and hCGbcf, was labeled with isothiocyanatophenylene
triamintetraacetic acid-europium (Wallac, Turku, Fin-
land) according to the manufacturer’s recommendations
[27] and used as a detection reagent in the 3 assays for
hCG, hCGb and hCGbcf, respectively.
The specificities of the applied IFMAs for hCG and
hCG variants are summarized in Table 1.
Purification of hCGa from seminal plasma by
immunoprecipitation
Seminal plasma samples from three normozoospermic
men were pooled and 1 ml of the pool was diluted 1:2
with modified RIPA buffer (10 mM Tris-HCl pH 7.4;
150 mM NaCl; 1% NP-40; 0.25% Na-deoxycholate, com-
plete Mini Protease Inhibitor Cocktail (Roche Diagnos-
tics) and 15 μl monoclonal antibody (4 mg/ml; Code
INN-hFSH-132; [18]). The mixture was incubated over-
n i g h ta t4 ° Co nar o t a r ys h a k e r .AP r o t e i n - Ga g a r o s e
resin (Upstate) was added and samples were incubated
for further 2 h at 4°C. Thereafter, samples were centri-
fuged, supernatant removed and the Protein-G agarose
resin was washed 5 times with modified RIPA buffer.
The Protein-G agarose resin was heated to 95°C for 10
m i ni n5 0μl modified RIPA buffer and centrifuged at
16,000 g for 10 min. The pellet was discarded and the
hCGa-containing supernatant stored at -20°C.
Digestion with glycosidase
hCGa purified from seminal plasma by IP, as described
a b o v e( 2 . 4 . )a n d ,f o rc o m p a r a t i v ep u r p o s e s ,l a r g ef r e e
hCGa purified by HPLC from supernatant of HEK293
stably transfected with b2AR and specifically stimulated
with 10 μM isoproterenol [28], as well as the frozen
Table 1 Specificity of IFMAs for hCG and/or hCG-variants
Assay type Assay specificity Capture mAb
Epitope localization
Detection mAb Epitope localization
hCG hCG intact ab heterodimer, bioactive;
hCGn nicked ab heterodimer, nicks in the region of aa hCGb44-48
INN-hCG-45
c3
hCGb loop 2
INN-hCG-22
b2
hCGb loops 1+3
aa 20-25+68-77
hCGb hCGb intact non-combined free hCGb-subunit, aa hCGb1-145;
hCGbcf core fragment of hCGb; aa hCGb6-40 linked to hCGb55-92;
hCGbn nicked hCGb, nicks in the region of aa hCGb44-48
INN-hCG-68
b7
hCGbcf
INN-hCG-22
hCGbcf hCGbcf-only INN-hCG-106
b11
hCGbcf
INN-hCG-22
hCGa hCGa intact non-combined free a-subunit of hCG; aa hCGa1-92 INN-hCG-72
a6
hCGa 33-42
INN-hFSH-158
a5
Loop 3 (Tyr 65)
Abbreviations and definitions for hCG and hCG-derived molecules as put forward by the IFCC Working Group for Standardization of hCG (Berger et al., 2002)
aa ... amino acids
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1
st International Reference Preparation for Immunoassay
of hCGa (1
st IRP hCGa 99/720) were deglycosylated
with peptide N-glycanase PNGase F (New England Bio-
Labs). For digestion under non-reducing conditions to
remove the glycan at Asn
52 [29,30], 15 μl samples
equivalent to 150 ng hCGa were incubated with 1.5 μl
0.5 M sodium phosphate buffer (pH 7.5), 1.5 μlN P - 4 0
and 1 μl Enzyme (PNGase F, 500 U) for 2 hrs at 37°C.
For digestion under reducing conditions to remove both
glycan moieties, samples were incubated with 1.5 μl 10×
denaturing buffer (5% SDS, 10% b-mercaptoethanol) for
10 min (95°C) and put on ice prior to deglycosylation.
Western Blot
Samples were diluted with sample buffer to 25 μl, sepa-
rated via gel electrophoresis on 4% stacking and 13%
separating gels and transferred to an Immun-Blot™
polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories). Membranes were probed with mouse
monoclonal antibody INN-hFSH-132 at a dilution of
1:2,000 for blots under non-reducing conditions and
rabbit hCGa antiserum at a dilution of 1:10,000 for
reduced proteins, respectively. Detection was performed
with HRP-conjugated secondary antibodies (Promega),
chemoluminescent substrate (Amersham ECL™ Wes-
tern Blotting Analysis System, GE Healthcare) and expo-
sure to ECL Hyperfilm (GE Healthcare).
Verification of hCGa by mass spectrometry
hCGa purified from seminal plasma by IP, as described
above (2.4.), was analyzed by SDS-PAGE, and the pro-
tein band at 24 kDa was excised from the gel and
digested with endoproteinase Lys-C [EC 3.4.21.50]
(Sigma-Aldrich, 1/20 w/w) in 100 mM H4HCO3 buffer
(pH = 8.0) for 2 hours at 37°C. The digest was analyzed
using nano-HPLC consisting of an UltiMate 3000 Sys-
tem (Dionex Corporation) connected online to a linear
iontrap mass spectrometer ThermoElectron Finnigan
LTQ) equipped with a nanospray ionization source. The
nanospray voltage was set at 1.6 kV, the heated capillary
w a sh e l da t2 0 0 ° C . M S / M S ,a n ds p e c t r aw e r es e a r c h e d
against a human protein database using SEQUEST
(LCQ BioWorks; ThermoFinnigan).
Statistical analyses
Results are expressed as mean values ± SEM. Statistical
differences among groups were calculated by unpaired
Student’s t-test and considered significant at P < 0.05.
Results
Characterization of patients: Serum hormone levels
Serum levels of TT, FSH, LH and hPRL were analyzed
in 21 patients with abnormal semen analyses (OAT n =
5, asthenozoospermia n = 2, teratozoospermia n = 1, oli-
gozoospermia n = 1, cryptozoospermia n = 8, azoosper-
mia n = 4) and compared with 6 control subjects with
normal semen analyses (Figure 2A). Patients with patho-
logic semen analysis findings showed no significant dif-
ferences in TT and LH serum levels, while hPRL levels
were significantly elevated (6.4 ± 0.7 vs. 4.5 ± 0.3 ng/ml;
P = 0.02). Mean serum FSH levels were significantly
increased in the abnormal group compared with con-
t r o l s( 9 . 7±1 . 4v s .3 . 1±0 . 1m I U / m l ;P = 0.0001), and
elevation of FSH levels (Figure 2B) was more pro-
nounced in patients diagnosed with cryptozoospermia
( 1 2 . 4±2 . 5m I U / m l ,P = 0.003) or azoospermia (12.5 ±
3.8 mIU/ml, P = 0.04) than those diagnosed with OAT
(6.6 ± 1.5 mIU/ml, P = 0.04).
*
hCG hCG hCG
*
***
A
C
[ng/ml] [mIU/ml] [mIU/ml] [ng/ml]
B
*
*
**
Figure 2 Serum and seminal plasma hormone levels in men
with impaired semen quality. (A) Serum T, FSH, LH and hPRL
levels in men with pathologic semen analyses findings (Path) and
normozoospermic controls (Norm). Men with impaired semen
quality showed significantly elevated FSH and hPRL levels. (B)
Serum FSH levels were significantly higher in men with
oligoasthenoterato- (OAT), crypto- (C) or azoospermia. (C) Hormone
variants analyzed in seminal plasma revealed significantly lower
hCGa levels in patients with abnormal semen analyses compared
with controls. Statistical significance was determined by unpaired
Student’s t-test (* P < 0.05; ** P < 0.001).
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abnormal semen analysis results
Hormone and hormone derivative levels were deter-
mined by respective IFMAs in seminal plasma speci-
mens from 29 patients with abnormal semen analyses
and compared with samples from 16 control subjects
with normal semen analyses (Table 2). hPL and hCGbcf
levels were similarly low in both groups, with several
samples below the detection limit preventing statistical
evaluation. hCGb, holo-hCG, hGH and hPRL levels
were not significantly different in the two cohorts (Fig-
ure 2B). However, free hCGa levels were significantly
lower in patients with pathologic semen analysis find-
ings (1346 ± 191 vs. 2753 ± 533 ng/ml; P = 0.022).
Decreased seminal plasma holo-hCG levels in patients
with decreased sperm count
In patients with impaired semen quality, the highest
variability of all analyzed hormones was observed for
holo-hCG (0.279 ± 0.101 ng/ml, Table 2). Patients with
astheno-, terato- or asthenoteratozoospermia had higher,
but statistically insignificant, hCG seminal plasma levels.
On the other hand, patients diagnosed with reduced
sperm counts (oligo-, oligoasthenoterato-, crypto- or
azoospermia; n = 23) had significantly reduced hCG
levels compared with normozoospermic men (0.097 ±
0.022 vs. 0.203 ± 0.040 ng/ml, P =0 . 0 2 8 ,F i g u r e3 A ) .
While hCGb levels were not significantly different (1.80
± 0.27 vs. 2.05 ± 0.29 ng/ml, P = 0.55, Figure 3B), mean
hCGa levels were significantly reduced in patients with
reduced sperm counts (1237 ± 197 vs. 2753 ± 533 ng/
ml, P = 0.015, Figure 3C). Given the fact that hCG as
well as hCGa were similarily reduced by approximately
50-60% in both cohorts, the ratio of hCGa/hCG was
analyzed and found to be comparable (normozoosper-
mia: 25.7 ± 6.1 × 10
3, reduced sperm count: 17.9 ± 3.2
×1 0
3, Figure 3D). Patients with astheno-, terato- or
asthenoteratozoospermia had a strongly reduced hCGa/
hCG ratio (2.6 ± 0.5 × 10
3, Figure 3D).
Genuine large hCGa in seminal plasma
Given the high free hCGa levels in seminal fluid com-
pared with serum (approximately 10,000-fold higher, as
described previously [13]) and the decreased levels in
seminal plasma of patients with poor semen analysis,
the hormone derivative from these patients was purified
and investigated in more detail.
Under non-reducing conditions, hCGa dissociated
from pregnancy-derived holo-hCG migrated as an
approximately 22 kDa band (Figure 4A). Large free
hCGa, which is unable to associate with b-subunits due
to larger N-linked sugar chains [31], had an apparent
molecular mass (Mr,app)o f2 4k D a .h C G a isolated form
seminal plasma migrated comparable with HEK293-
derived large free hCGa. After digestion of the glycan at
Asn
52, the dissociated standard and HEK293-derived
large free hCGa showed identical Mr,app of 18 kDa,
while protein isolated from seminal fluid migrated as a
diffuse band of approximately 19 - 20 kDa (Figure 4A).
When both glycan moieties were removed, all three
hCGa variants tested resulted a 15 kDa deglycosylated
protein.
The biochemical identity of hCGa purified from semi-
nal fluid was verify by nano-HPLC MS/MS analysis after
digestion with endoproteinase Lys-C (Table 3).
Discussion
Protein and glycoprotein hormone-like substances have
been described previously in human seminal fluid, but
the lack of antibodies and consequent sandwich assays
with clearly defined glycoprotein hormone variant
recognition patterns meant that a general variant profile
of these markers and their relationship to fertility distur-
bances could not be accomplished. We analyzed the
profile of endocrine paramete r si np a t i e n t sw i t ha b n o r -
mal semen analysis findings in comparison to normo-
zoospermic men to elucidate a putative
pathophysiological role of glycoprotein hormone var-
iants in spermatogenesis disorders.
To characterize the patient cohort serum levels of TT,
FSH, LH and hPRL were analyzed. In accordance with
previous reports [32], significantly higher serum hPRL
levels were found in men with abnormal semen analysis,
but still within the normal range, indicating that the
patients did not suffer from hyperprolactinemia. Mean
serum FSH levels were above the normal reference
range (1.3 - 8.4 mIU/ml [33]) in patients with abnormal
semen analysis and highest in patients with cryptozoos-
permia and azoospermia, reflecting a decline in function
of seminiferous tubules [34]. High heterogeneity of FSH
levels indicated that men with both obstructive and
non-obstructive azoospermia were included in the study
cohort.
In seminal plasma levels of hCGa were found to be
significantly lower in patients with abnormal semen ana-
lyses. Similarly, in patients with reduced sperm count,
intact hCG levels were significantly lower. In these
patients, the hCGa/hCG ratio was comparable with nor-
mozoospermic men, indicating co-secretion of free
hCGa and hCGa associated with hCGb.C o m p a r e d
with hCG, free hCGb is present in seminal plasma in an
approximately 10-fold, and free hCGa in an approxi-
mately 10,000-fold excess. Thus, free hCGa appeared as
large subunit, distinct from the a subunit present in
hCG [31] and unable to associate with the available b
subunit. Non-associable and associated hCGa seem to
be secreted at a constant ratio of approximately
10,000:1, the latter being the rate limiting subunit of
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Diagnosis Age [years] Sperm counts hCGa hCGb hCGbcf hCG hGH hPL hPRL
range mean range mean range mean range mean range mean range mean range mean range mean range mean
N (n = 16) 31-57 37.1 ±
1.7
25.0-
87.5
53.7 ±
5.1
726-
8754
2753 ±
533
0.23-
4.16
2.05 ±
0.29
<0.005-
0.010
0.007 ±
0.001
0.016-
0.578
0.203 ±
0.040
0.004-
0.090
0.023 ±
0.006
<0.005-
0.738
0.095 ±
0.072
4.00 ±
16.11
7.82 ±
0.86
Path (n =
29)
21-48 34.1 ±
1.5
0-109.9 n.d. 86-
4400
1346 ±
191
0.18-
10.00
2.22 ±
0.38
<0.005-
0.140
n.d. <0.02-
2.260
0.279 ±
0.101
<0.005-
0.086
0.028 ±
0.005
<0.005-
1.760
n.d. 2.92-
17.57
7.54 ±
0.78
AS (n = 3) 25-42 34.0 ±
4.9
35.6-
109.9
77.2 ±
21.9
110-
1500
820 ±
402
0.36-
10.0
5.29 ±
2.78
<0.05-
0.14
n.d. 0.060-
2.260
0.840 ±
0.711
<0.005-
0.030
n.d. 0.016-
1.760
0.629 ±
0.566
n.t./7.50 n.d.
T (n = 1) 42 n.d. 109.3 n.d. 2500 n.d. 2.8 n.d. <0.005 n.d. 0.82 n.d. 0.007 n.d. 0.21 n.d. n.d. n.d.
AST (n =
2)
30 n.d. n.d/
19.5
n.d. 1100-
4400
n.d. 2.10-
2.16
n.d. <0.005-
0.024
n.d. 0.5-1.3 n.d. n.t./0.006 n.d. <0.005-
0.160
n.d. n.t./7.38 n.d.
O (n = 2) 23-45 n.d. 13.1-
16.1
n.d. 669-
1500
n.d. 0.40-
1.02
n.d. <0.005/n.
d.
n.d. <0.02-
0.041
n.d. <0.005-
0.050
n.d. 0.007 n.d. n.t./3.87 n.d.
OAT (n =
7)
22-36 29.0 ±
1.9
0.6-6.2 3.7 ±
0.8
610-
1938
1107 ±
176
0.56-
2.00
1.38 ±
0.24
<0.005 <0.005 <0.02-
0.234
0.102 ±
0.037
<0.005-
0.049
0.029 ±
0.007
<0.02 <0.02 3.34-8.09 5.44 ±
1.16
C (n = 8) 21-45 34.5 ±
2.7
<0.3-
0.3
n.d. 192-
3661
1522 ±
428
0.70-
3.39
2.04 ±
0.41
<0.005 <0.005 <0.02-
0.420
0.122 ±
0.016
<0.005-
0.086
0.039 ±
0.012
<0.02 <0.02 2.92-
17.57
8.85 ±
1.73
A (n = 6) 31-48 39.8 ±
3.3
0 0 86-
2630
1108 ±
394
0.18-
5.21
2.35 ±
0.82
<0.005 <0.005 <0.02-
0.120
0.066 ±
0.018
0.003-
0.037
0.016 ±
0.006
<0.02 <0.02 7.00-8.86 7.88 ±
0.34
Patients were grouped according to spermiogram (WHO 1995): normozoospermia (N), abnormal semen analysis results (Path), asthenozoospermia (AS), teratozoospermia (T), asthenoteratozoospermia (AST),
oligozoospermia (O), oligoastheoteratozoospermia (OAT), cryptozoospermia (C), azoospermia
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0holo-hCG association. On the other hand, the hCGa/
hCG ratio was reduced in patients with astheno-, terato-
or asthenoteratozoospermia, although the limited num-
ber of patients in this cohort require confirmation of
these alterations by further research. Other hormone
variants were not significantly different in the cohorts
tested and generally expressed at low levels.
The pathophysiological role of reduced hCGa and
h C Gl e v e l si su n c e r t a i n .W ep r e v i o u s l ys h o w e dh C G b
expression in the testis in peritubular and presumably
Leydig cells [13]. Due to its structural homology to LH,
hCG is able to stimulate T production by Leydig cells.
Thus, it could be hypothesized that hCG expression in
the testis serves as a local backup system to sustain
basal T secretion. However, hCG levels in seminal
plasma were very low (0.016 - 0.578 ng/ml in normo-
zoospermic men). During pregnancy, the serum ratios of
hCG to the free a and b subunits is usually in the range
in 100:1, while in seminal plasma, hCGa is found in
10,000-fold excess (726 - 8754 ng/ml in normozoosper-
mic men) of the holo-hormone.
The molecular function of the free hCGa is still unre-
solved, and no receptors for the free subunit have yet
been described. Free hCGa has been reported to stimu-
late endometrial stromal cell differentiation synergisti-
cally with progesterone [35]. Antisense hCGa RNA
reduced the tumorigenic potential of lung cancer cells
[36] and hCGa inhibited growth of prostatic stromal
cells [37]. In the male reproductive tract, several sources
of free hCGa have been described, in particular the
prostate [37-39]. Moreover, significant amounts of
hCGa have been detected in seminal vesicle fluid, and
minor concentrations in the testis [13,40]. Herein, we
demonstrate that hCGa purified from seminal plasma
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Figure 3 Reduced hCG and free hCGa seminal plasma levels in men with reduced sperm count. (A) Patients with reduced sperm count
(n = 23) showed significantly lower free holo-hCG levels compared with normozoospermic controls (n = 16), while (B) free hCGb levels were
not affected. (C) Similar to holo-hCG, free hCGa levels were significantly lower in men with reduced sperm count, resulting in (D) hCGa/hCG
ratios comparable to normozoospermic men, while men with asthenozoospermia, teratozoospermia or asthenoteratozoospermia (AS, T, AST; n =
6) showed reduced hCGa/hCG ratios. Red bars indicated mean ± SEM. (A-C) Statistical significance was calculated by Student’s t-test (* P < 0.05).
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Page 7 of 10had the Mr,app of large free hCGa, which is incapable of
associating with b-subunits due to larger N-linked sugar
chains [31]. Interestingly, the large free a subunit iso-
lated from seminal fluid showed a different glycosylation
p a t t e r nt h a nl a r g eh C G a produced from HEK cells sta-
bly transfected with b2AR and stimulated with isoproter-
enol [28]. While the latter appeared to be more highly
glycosylated at Asn
52, seminal plasma-derived hCGa
appeared to be more highly glycosylated at Asn
78.T h i s
might reflect distinct molecular functions of large free
hCGa variants from different sources due to alternative
glycosylation. After total deglycosylation, hCGa derived
from seminal plasma, HEK cells and dissociated from
the heterodimeric hCG showed identical Mr,app,i n d i c a t -
ing identical amino acid backbone and genuineness of
large free hCGa in seminal plasma as shown by nanos-
pray MS. Thus, due to its unique gylcosylation pattern,
free hCGa purified from seminal plasma, where it is
normally present in high concentrations and is reduced
in men with abnormal semen analysis, represents a pro-
mising variant to investigate the unresolved molecular
function of the free subunit.
Conclusions
Levels of free hCGa, by far the most abundant hCG var-
iant in seminal plasma, were significantly reduced in
men with abnormal semen analyses. Additionally, in
men with reduced sperm counts, holo-hCG levels were
accordingly lower, indicating a pathophysiological rele-
vance of these hormone variants in spermatogenesis.
hCGa in seminal plasma was identified as being a highly
glycosylated large free subunit with a unique glycosyla-
tion pattern. Alternative glycosylation clearly might
modify the function of the hormone subunit, thus free
large hCGa purified from seminal plasma represents a
promising molecular entity to further investigate the
physiological role of free hCGa in spermatogenesis.
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